All In Biotech

Drug Trial Radar · NCT04985942

Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: May 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 485 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

485

Actual

Start

Jul 30, 2021

Primary completion

Feb 22, 2024

Study completion Feb 27, 2024

Sponsor

Lead sponsor
Intra-Cellular Therapies, Inc.Industry
Sponsor type
Industry
First posted
Aug 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

Conditions

  • Major Depressive Disorder

Interventions

  • LumateperoneDrug

    Lumateperone 42 mg capsules administered orally, once daily.

  • PlaceboDrug

    Matching capsules administered orally, once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Montgomery-Åsberg Depression Rating ScaleTime frame: Day 43

Locations

54 sites in 6 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Phoenix, Arizona

  • Clinical Site

    Glendale, California

  • Clinical Site

    Oceanside, California

  • Clinical Site

    Redlands, California

  • Clinical Site

    Temecula, California

  • Clinical Site

    Upland, California

  • Clinical Site

    Fort Lauderdale, Florida

  • Clinical Site

    Jacksonville, Florida

  • Clinical Site

    Orlando, Florida

  • Clinical Site

    Decatur, Georgia

  • Clinical Site

    Boston, Massachusetts

  • Clinical Site

    Berlin, New Jersey

  • Clinical Site

    Toms River, New Jersey

  • Clinical Site

    Cedarhurst, New York

  • Clinical Site

    Austin, Texas

  • Clinical Site

    Burgas, Bulgaria

  • Clinical Site

    Kazanlak, Bulgaria

  • Clinical Site

    Pleven, Bulgaria

  • Clinical Site

    Rousse, Bulgaria

  • Clinical Site

    Tsarev Brod, Bulgaria

  • Clinical Site

    Veliko Tarnovo, Bulgaria

  • Clinical Site

    Veliko Tarnovo, Bulgaria

  • Clinical Site

    Vratsa, Bulgaria

  • Clinical Site

    Brno, Czechia

  • Clinical Site

    Brno, Czechia

  • Clinical Site

    Ostrava, Czechia

  • Clinical site

    Pilsen, Czechia

  • Clinical Site

    Prague, Czechia

  • Clinical Site

    Prague, Czechia

  • Clinical Site

    Budapest, Hungary

  • Clinical Site

    Budapest, Hungary

  • Clinical Site

    Budapest, Hungary

  • Clinical Site

    Gyöngyös, Hungary

  • Clinical Site

    Guwahati, Assam, India

  • Clinical Site

    Ahmedabad, Gujarat, India

  • Clinical Site

    Jūnāgadh, Gujarat, India

  • Clinical Site

    Vadodara, Gujarat, India

  • Clinical Site

    Mangaluru, Karnataka, India

  • Clinical Site

    Mysore, Karnataka, India

  • Clinical Site

    Kozhikode, Kerala, India

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.